Clinical Trial Update: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety and tolerability study for an investigational schizophrenia drug sponsored by Otsuka has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Investigational drug (name not disclosed)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED